United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

26 May 2017
Change (% chg)

$-2.17 (-0.86%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BIIB.OQ


Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)


Beta: 0.82
Market Cap(Mil.): $53,198.49
Shares Outstanding(Mil.): 212.12
Dividend: --
Yield (%): --


  BIIB.OQ Industry Sector
P/E (TTM): 15.73 14.27 17.41
EPS (TTM): 15.95 -- --
ROI: 19.24 -7.17 -5.42
ROE: 31.91 -6.63 -4.68

UPDATE 1-Deadly brain infection in German MS patient prompts Roche investigation

ZURICH, May 24 A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday.

May 24 2017

Celgene's multiple sclerosis drug succeeds in late-stage trial

May 22 Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal of reducing annualized relapse rate, when compared to Biogen Inc's Avonex, in a second late-stage study.

May 22 2017

BRIEF-Biogen acquires Remedy Pharmaceuticals' late-stage drug cirara

* Biogen acquires Remedy Pharmaceuticals' late-stage drug cirara

May 18 2017

BRIEF-Paulson & Co Inc takes share stake in Dish Network, Monsanto

* Paulson & Co Inc takes share stake of 3.5 million shares in Dish Network Corp

May 15 2017

Biogen beats securities fraud lawsuit over multiple sclerosis drug sales

Biogen Inc has won the dismissal of a proposed shareholder class action claiming executives misled investors about the effect on sales of the death of a patient who had taken the company's new multiple sclerosis drug Tecfidera.

May 15 2017

BRIEF-Biogen former CEO Scangos's 2016 compensation was $17.7 mln

* Biogen Inc former CEO George Scangos's 2016 total compensation $17.7 million versus $16.9 million in 2015 - sec filing Source text - http://bit.ly/2oKp4LQ Further company coverage:

Apr 26 2017

Biogen profit beats on surprisingly strong Spinraza sales

Biogen Inc's quarterly profit blew past analysts' estimates, helped by higher-than-expected sales of its recently launched spinal muscular atrophy drug, Spinraza.

Apr 25 2017

UPDATE 3-Biogen profit beats on surprisingly strong Spinraza sales

* Shares rise 5.4 pct (Adds conference call details, analyst comments; updates shares)

Apr 25 2017

BRIEF-Biogen CFO says expects Spinraza adoption to ramp up going forward: Conf Call

* Biogen says "we are working to add more assetts to our pipeline": Conf Call

Apr 25 2017

Drugmaker Biogen's revenue rises 3 percent

April 25 Biogen Inc reported a 3 percent rise in quarterly revenue, helped by higher-than-expected sales of its newly launched spinal muscular atrophy drug, Spinraza.

Apr 25 2017

More From Around the Web


  Price Chg
Johnson & Johnson (JNJ.N) $126.92 -0.61
Pfizer Inc. (PFE.N) $32.14 -0.02
Novartis AG (NOVN.S) CHF78.60 -0.50
Merck & Co., Inc. (MRK.N) $64.92 -0.12
Roche Holding Ltd. (ROG.S) CHF266.60 -0.60
Roche Holding Ltd. (RO.S) CHF267.75 +0.25
Bayer AG (BAYGn.DE) €116.70 -0.05
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.74 +0.43
GlaxoSmithKline plc (GSK.L) 1,643.50 +25.50

Earnings vs. Estimates